Aggressive Variant Prostate Carcinoma: Clinical Trials

2 trials for Aggressive Variant Prostate Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting. 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 22Active not recruiting 1, Recruiting 1

Follow Aggressive Variant Prostate Carcinoma: new trials by email Literature Review of Aggressive Variant Prostate Carcinoma trials Research Report on Aggressive Variant Prostate Carcinoma

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Zanzalintinib in Men With Aggressive Variant Prostate Cancer
Zanzalintinib - Aggressive Variant Prostate Carcinoma
Phase 2RecruitingDeepak Kilari302026-08-192026-08-28
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
Cabazitaxel, Carboplatin, Cetrelimab - Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center1202020-12-292026-09-09

Narrower conditions

Prostatic Neoplasms (1)

Broader conditions

Genital Diseases (1)  ·  Genital Diseases, Male (1)  ·  Genital Neoplasms, Male (1)  ·  Male Urogenital Diseases (1)  ·  Neoplasms (1)  ·  Neoplasms by Site (1)  ·  Prostatic Diseases (1)  ·  Urogenital Diseases (1)  ·  Urogenital Neoplasms (1)

Interventions

Carboplatin (1)  ·  XRP6258 (1)  ·  cabazitaxel (1)  ·  niraparib (1)

Sponsors

Deepak Kilari (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (2)

Top investigators

Ana Aparicio (1)  ·  Deepak Kilari, MD (1)